Control Bionics (ASX:CBL) 3-Year RORE % : -26.53% (As of Dec. 2025)


What is Control Bionics 3-Year RORE %?

Control Bionics ASX:CBL -0.67% 3-Year RORE % is -26.53 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 782 Medical Devices & Instruments companies, Control Bionics ranks worse than 71.36% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Control Bionics's 3-Year RORE % for the quarter that ended in Dec. 2025 was -26.53%.

The industry rank for Control Bionics's 3-Year RORE % or its related term are showing as below:

ASX:CBL's 3-Year RORE % is ranked worse than
71.36% of 782 companies
in the Medical Devices & Instruments industry
Industry Median: -4.23 vs ASX:CBL: -26.53

Control Bionics  (ASX:CBL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Control Bionics 3-Year RORE % Related Terms


Control Bionics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Control Bionics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics 3-Year RORE % Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 4.19 -16.56 -27.59

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.88 -16.56 -20.29 -27.59 -26.53

ASX:CBL vs ABT, SYK, MDT: 3-Year RORE % Comparison

For the Medical Devices subindustry, Control Bionics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Control Bionics 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Control Bionics's 3-Year RORE % falls into.



Control Bionics 3-Year RORE % Calculation

Control Bionics's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.02--0.046 )/( -0.098-0 )
=0.026/-0.098
=-26.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -26.53 mean?
Control Bionics (ASX:CBL) has a 3-Year RORE % of -26.53 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #558 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 71.4%.
Is Control Bionics' 3-Year RORE % too high?
Control Bionics' current 3-Year RORE % is -26.53. Based on the distribution chart, Control Bionics ranks #558 out of 782 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #558 out of 782 companies for 3-Year RORE %. This places Control Bionics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Control Bionics and its competitors. Control Bionics's current 3-Year RORE % is -26.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current 3-Year RORE % is -26.53. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current 3-Year RORE % is -26.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.